Hepatitis C SIG: Navigating the road to elimination of HCV in the U.S.

5 (1 vote)

Recorded On: 11/09/2018

This program covers the key components that support efforts to define a program toward eradication of HCV in the U.S.  The program is centered around modeling, engagement of individuals difficult to link to care and screening efforts.  Access to care and the role of advocacy is instrumental and approaches toward successful advocacy will also be discussed.  

John W. Ward

John W. Ward, MD created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health. He received his medical training at the University of Alabama at Birmingham and University of Washington and currently is a Professor in the Hubert Department of Global Health, Rollins School of Public Health, Emory University. Dr. Ward is an advisor to WHO Geneva, PAHO, WPRO, and the African Union. Dr. Ward chairs the AASLD Task Force for Hepatitis Elimination. Over a 13-year tenure, Dr. Ward directed the US CDC Division of Viral Hepatitis including hepatitis surveillance, prevention, and research. At the national level, Dr. Ward developed recommendations for hepatitis A and hepatitis B vaccination, hepatitis B and hepatitis C screening, and authored the first national action plan for hepatitis prevention. Dr. Ward guided the launch of pioneer HCV elimination programs. Previously, Dr. Ward led US HIV/AIDS surveillance. Ward has authored over 150 scientific publications. 

Anne Spaulding

Jason Grebely

Nancy S. Reau (Moderator)

Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

 

Stacey Trooskin

Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania.  She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.

Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee.  She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.

Michael Ninburg

Rachel Church

Rachel Church, PhD is a Research Assistant Professor in the Department of Pharmacotherapy and Experimental Therapeutics within the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill. She also serves as the Director of UNC Organ Injury Biomarker Core that is part of UNC’s Institute for Drug Safety Sciences. Dr. Church received her B.S. degree from North Carolina State University and her Ph.D. from UNC Chapel Hill. Given the shortcomings of traditional measurements, the research of Dr Church aims to broaden the use and understanding of candidate biomarkers of organ injury, with a primary focus on clinical drug-induced liver injury. Dr. Church is also interested in identifying novel applications for traditional biomarkers that will improve their interpretation. Prior to joining UNC, Dr. Church was a Research Investigator at the Hamner Institutes for Health Sciences. 

Andrew J. Muir (Moderator)

Andrew Muir, MD, FAASLD is a gastroenterologist whose research activitiesare focused on developing innovative treatments for a variety of liverdiseases. Through his work at the Durham Veterans Administration MedicalCenter, Dr. Muir has participated in the development programs of many of thedirect acting antiviral agents that have revolutionized hepatitis C care. Heassumed the leadership of the Gastroenterology and Hepatology Research programat DCRI in 2010 and has expanded the research portfolio to include other liverdisorders and gastroenterology outcomes. His particular interests include viralhepatitis, primary sclerosing cholangitis, and liver transplantation. He alsohas a longstanding interest in healthcare disparities.

Key:

Complete
Failed
Available
Locked
Session I: Evolution of the Current Standard of Care
Screening: Are we targeting to correct populations?
Open to view video.
Open to view video. Presenter: John Ward
Session II: Defining an elimination strategy
HCV and the prison
Open to view video.
Open to view video. Presenter: Anne Spaulding
Can we achieve HCV elimination without strategies for marginalized people who inject drugs?    
Open to view video.
Open to view video. Presenter: Jason Grebely
Panel Discussion/Q&A
Open to view video.
Open to view video. Moderator: Nancy Reau
Session III: Advocacy- what does this mean    
Effective grass roots movement 
Open to view video.
Open to view video. Presenter: Stacey Trooskin
Can patients change bureaucracy?     
Open to view video.
Open to view video. Presenter: Michael Ninburg
Can a physician advocate?      
Open to view video.
Open to view video. Presenter: Robert Gish
Panel Discussion/Q&A
Open to view video.
Open to view video. Moderator: Andrew Muir
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.